NEW YORK, Dec 23 (Reuters Breakingviews) - The pandemic has been good for U.S. diagnostic-test provider Quidel (QDEL.O). But 2023 revenue at $732 million, according to estimates compiled by Refinitiv, would only be about half the top line in 2021. The purchase will help Quidel expand overseas. That may help explain why investors sent the stock down more than 15% after the deal was unveiled on Thursday. The buyout group bought Ortho from Johnson & Johnson (JNJ.N) for about $4 billion in 2014.

Source: The North Africa Journal December 23, 2021 09:05 UTC